{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that a-synuclein aggregation is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The text explicitly links a-synuclein aggregation to Lewy body formation, a core pathological feature of PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro studies show that A53T and A30P mutations promote a-synuclein aggregation to form amyloid fibrils resembling Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assay directly models the disease mechanism of a-synuclein aggregation in PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe controls (wild-type vs. mutant) or experimental replication for the aggregation assays.",
          "judgment": "No",
          "reasoning": "Lack of detailed controls and replication information in the text.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The in vitro aggregation assay is a standard method in a-synuclein research and has been validated in prior studies (e.g., Narhi et al., 1999).",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted as a validated tool for studying a-synuclein aggregation in PD.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath calculations are provided for the A53T mutation.",
          "judgment": "No",
          "reasoning": "The text lacks quantitative data for statistical evaluation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes three control variants (A53T, A30P, E46K) but does not specify total numbers or criteria for classification.",
          "judgment": "10 or less",
          "reasoning": "The text explicitly mentions only three variants, likely fewer than 10 total controls.",
          "next_step_or_outcome": "Functional evidence strength is PS3_supporting"
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-synuclein aggregation is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The text explicitly links a-synuclein aggregation to Lewy body formation, a core pathological feature of PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro studies show that A53T and A30P mutations promote a-synuclein aggregation to form amyloid fibrils resembling Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assay directly models the disease mechanism of a-synuclein aggregation in PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe controls (wild-type vs. mutant) or experimental replication for the aggregation assays.",
          "judgment": "No",
          "reasoning": "Lack of detailed controls and replication information in the text.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The in vitro aggregation assay is a standard method in a-synuclein research and has been validated in prior studies (e.g., Narhi et al., 1999).",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted as a validated tool for studying a-synuclein aggregation in PD.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath calculations are provided for the A30P mutation.",
          "judgment": "No",
          "reasoning": "The text lacks quantitative data for statistical evaluation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes three control variants (A53T, A30P, E46K) but does not specify total numbers or criteria for classification.",
          "judgment": "10 or less",
          "reasoning": "The text explicitly mentions only three variants, likely fewer than 10 total controls.",
          "next_step_or_outcome": "Functional evidence strength is PS3_supporting"
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-synuclein aggregation is a major event in the development of Lewy body pathology in PD.",
          "judgment": "Yes",
          "reasoning": "The text explicitly links a-synuclein aggregation to Lewy body formation, a core pathological feature of PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The E46K mutation is described as promoting a-synuclein aggregation in autosomal dominant parkinsonian syndromes.",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assay directly models the disease mechanism of a-synuclein aggregation in PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe controls (wild-type vs. mutant) or experimental replication for the aggregation assays.",
          "judgment": "No",
          "reasoning": "Lack of detailed controls and replication information in the text.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The in vitro aggregation assay is a standard method in a-synuclein research and has been validated in prior studies (e.g., Narhi et al., 1999).",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted as a validated tool for studying a-synuclein aggregation in PD.",
          "next_step_or_outcome": "Functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analyses or OddsPath calculations are provided for the E46K mutation.",
          "judgment": "No",
          "reasoning": "The text lacks quantitative data for statistical evaluation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study includes three control variants (A53T, A30P, E46K) but does not specify total numbers or criteria for classification.",
          "judgment": "10 or less",
          "reasoning": "The text explicitly mentions only three variants, likely fewer than 10 total controls.",
          "next_step_or_outcome": "Functional evidence strength is PS3_supporting"
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    }
  ]
}